ABSTRACT
PURPOSE: The aim of the present study was to determine bone density in designated implant sites using cone beam computed tomography (CBCT) and to evaluate possible correlations between age, gender, insertion torque measurements, and resonance frequency analysis (RFA) values. MATERIALS AND METHODS: Completely and partially edentulous patients were treated with implants between 2007 and 2008 and evaluated retrospectively. The preoperative examination included a panoramic radiograph, CBCT, diagnostic casts, and a clinical examination of the jaws. With the CBCT scans, bone densities were recorded in Hounsfield units (HU). Insertion torque values and implant stability measurements (via RFA) were also noted. RESULTS: Mean bone density and insertion torque values were 623 ± 209 HU and 42.4 ± 4 Ncm, respectively, for the 82 implants placed. Mean primary stability (implant stability quotient) was 62.4 ± 8. The differences in mean bone density at implant sites in the mandible (717 ± 204 HU) and the maxilla (490 ± 128 HU) were statistically significant for all patients (P < .05). There was a statistically significant relationship between bone density values and insertion torque measurements for implant sites in the anterior mandible (r = 0.562, P < .05), as well as between bone density and RFA values for men (r = 0.412, P < .05). CONCLUSIONS: Bone density measurements using preoperative CBCT may be helpful as an objective diagnostic tool. These values, in conjunction with RFA values and insertion torque measurements, can provide the implant surgeon with an objective assessment of bone quality and may be especially useful where poor-quality bone is suspected.
Subject(s)
Bone Density/physiology , Cone-Beam Computed Tomography/methods , Dental Implantation, Endosseous/methods , Dental Implants , Adult , Age Factors , Dental Arch/diagnostic imaging , Dental Arch/surgery , Dental Prosthesis Retention , Female , Humans , Jaw, Edentulous/diagnostic imaging , Jaw, Edentulous/surgery , Jaw, Edentulous, Partially/diagnostic imaging , Jaw, Edentulous, Partially/surgery , Male , Mandible/diagnostic imaging , Mandible/surgery , Maxilla/diagnostic imaging , Maxilla/surgery , Middle Aged , Models, Dental , Pilot Projects , Radiography, Panoramic , Retrospective Studies , Sex Factors , Torque , Transducers , VibrationABSTRACT
Sialorrhea or excessive salivation, and drooling, are common and disabling manifestations in different neurological disorders. A review is made of the literature, based on a PubMed search, selecting those articles describing clinical trials involving the injection of botulinum toxin A in the salivary glands of patients with different diseases characterized by sialorrhea. The most frequently treated diseases were infant cerebral palsy (30%), Parkinson's disease (20%) and amyotrophic lateral sclerosis (15%). Over half of the authors injected the product into the parotid glands, 9.5% into the submaxillary glands, and 38% into both. The total doses of toxin injected varied from 10-100 units of Botox or 30-450 units of Dysport according to the different authors. A reduction was observed in the production of saliva following these injections, and the duration of the therapeutic effect was 1.5-6 months. Six articles (30%) described the presence of adverse effects such as dysphagia, xerostomia and chewing difficulties. Most of the clinical studies involved small patient samples, with no blinding or randomization, and no control group. Moreover, no data are available on the efficacy and adverse effects of treatment in the context of long-term prospective studies. The effective therapeutic dose and ideal form of application remain to be established, and require the conduction of further controlled clinical trials involving large sample sizes.
Subject(s)
Botulinum Toxins, Type A/administration & dosage , Neurotoxins/administration & dosage , Sialorrhea/drug therapy , Humans , Injections, Intralesional , Salivary Glands , Sialorrhea/etiologyABSTRACT
No disponible
Sialorrhea or excessive salivation, and drooling, are common and disabling manifestations in different neurological disorders. A review is made of the literature, based on a PubMed search, selecting those articles describing clinical trialsinvolving the injection of botulinum toxin A in the salivary glands of patients with different diseases characterized by sialorrhea.The most frequently treated diseases were infant cerebral palsy (30%), Parkinsons disease (20%) and amyotrophic lateral sclerosis (15%). Over half of the authors injected the product into the parotid glands, 9.5% into the submaxillary glands, and 38% into both. The total doses of toxin injected varied from 10-100 units of Botox® or 30-450 units of Dysport®according to the different authors. A reduction was observed in the production of saliva following these injections, and the duration of the therapeutic effect was 1.5-6 months. Six articles (30%) described the presence of adverse effects such as dysphagia, xerostomia and chewing difficulties.Most of the clinical studies involved small patient samples, with no blinding or randomization, and no control group.Moreover, no data are available on the efficacy and adverse effects of treatment in the context of long-term prospective studies. The effective therapeutic dose and ideal form of application remain to be established, and require the conduction of further controlled clinical trials involving large sample sizes (AU)
